Athyrium Capital Management provided the capital for Debiopharm and Axa-backed breast cancer diagnostics system developer Agendia.
Agendia, a Netherlands-based cancer diagnostics technology provider backed by corporates Debiopharm and Axa, has closed $35m in financing from investment funds managed by asset management firm Athyrium Capital Management.
Founded in 2003, Agendia has developed an in vitro device called MammaPrint that studies the gene expression profile of a tissue sample supplied by a lymph-node positive breast cancer patient to diagnose the risk of the disease spreading to more distant organs or lymph nodes.
The product has received regulatory approval…
